Bio-Rad Laboratories (BIO) Non-Current Deferred Tax Liability (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $881.8 million in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 4.88% year-over-year to $881.8 million in Q1 2026; TTM through Mar 2026 was $881.8 million, a 4.88% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 29.51% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $881.8 million, down from $1.1 billion in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for BIO reached as high as $2.0 billion in Q1 2022 and fell as low as $818.0 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $1.3 billion across 5 years, with a median of $1.4 billion in 2023.
• Across the five-year window, Non-Current Deferred Tax Liability slumped 58.41% in 2022 and gained 29.51% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then dropped by 14.43% to $1.6 billion in 2023, then tumbled by 50.24% to $818.0 million in 2024, then climbed by 29.51% to $1.1 billion in 2025, then slipped by 16.76% to $881.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $881.8 million in Q1 2026, $1.1 billion in Q4 2025, and $872.6 million in Q3 2025.